Ghent University Academic Bibliography

Advanced

MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?

Monirath Hav UGent, Louis Libbrecht UGent, Liesbeth Ferdinande UGent, Piet Pattyn UGent, Stéphanie Laurent UGent, Marc Peeters UGent, Marleen Praet UGent and Patrick Pauwels UGent (2011) VIRCHOWS ARCHIV. 458(2). p.197-203
abstract
The aim of this study was to investigate murine double minute-2 (MDM2) gene copy number changes in colon carcinoma and to correlate these findings with an immunohistochemical analysis of MDM2 protein expression and histopathologic prognostic indicators of the tumors. The study included 80 cases of sporadic colon carcinomas. MDM2 protein expression was assessed by immunohistochemistry, and MDM2 gene status by fluorescence in situ hybridization. MDM2 gene amplification was detected in 18% of the 80 cases examined. A strong correlation was found between MDM2 gene amplification and the presence, intensity, and staining proportion of cytoplasmic MDM2 protein expression (p = 0.01). No correlation was found between MDM2 gene amplification and the well-established histopathologic prognostic factors. Given the correlation with gene amplification, we clearly demonstrated that cytoplasmic expression of MDM2 protein is true and relevant and that this finding has to be taken into account when immunohistochemistry would be used as a screening for MDM2 gene amplification in the near future. Targeting MDM2 could be a new approach in colon cancer therapy. The amplification status could be a predictive factor of the response to MDM2-targeted therapy.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
SUPPRESSOR, MESSENGER-RNA, INHIBITORS, ACTIVATION, SNP309, IN-VIVO, ONCOPROTEIN MDM2, P53 FUNCTION, CANCER-THERAPY, ACCELERATES TUMOR-FORMATION, Targeted treatment in colon carcinoma, Colon carcinoma, MDM2 in colon carcinoma, MDM2 gene amplification, MDM2, MDM2 protein expression
journal title
VIRCHOWS ARCHIV
Virchows Arch.
volume
458
issue
2
pages
197 - 203
Web of Science type
Article
Web of Science id
000286830000010
JCR category
PATHOLOGY
JCR impact factor
2.491 (2011)
JCR rank
28/78 (2011)
JCR quartile
2 (2011)
ISSN
0945-6317
DOI
10.1007/s00428-010-1012-7
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
2017026
handle
http://hdl.handle.net/1854/LU-2017026
date created
2012-02-02 18:49:34
date last changed
2012-03-22 15:30:55
@article{2017026,
  abstract     = {The aim of this study was to investigate murine double minute-2 (MDM2) gene copy number changes in colon carcinoma and to correlate these findings with an immunohistochemical analysis of MDM2 protein expression and histopathologic prognostic indicators of the tumors. The study included 80 cases of sporadic colon carcinomas. MDM2 protein expression was assessed by immunohistochemistry, and MDM2 gene status by fluorescence in situ hybridization. MDM2 gene amplification was detected in 18\% of the 80 cases examined. A strong correlation was found between MDM2 gene amplification and the presence, intensity, and staining proportion of cytoplasmic MDM2 protein expression (p = 0.01). No correlation was found between MDM2 gene amplification and the well-established histopathologic prognostic factors. Given the correlation with gene amplification, we clearly demonstrated that cytoplasmic expression of MDM2 protein is true and relevant and that this finding has to be taken into account when immunohistochemistry would be used as a screening for MDM2 gene amplification in the near future. Targeting MDM2 could be a new approach in colon cancer therapy. The amplification status could be a predictive factor of the response to MDM2-targeted therapy.},
  author       = {Hav, Monirath and Libbrecht, Louis and Ferdinande, Liesbeth and Pattyn, Piet and Laurent, St{\'e}phanie and Peeters, Marc and Praet, Marleen and Pauwels, Patrick},
  issn         = {0945-6317},
  journal      = {VIRCHOWS ARCHIV},
  keyword      = {SUPPRESSOR,MESSENGER-RNA,INHIBITORS,ACTIVATION,SNP309,IN-VIVO,ONCOPROTEIN MDM2,P53 FUNCTION,CANCER-THERAPY,ACCELERATES TUMOR-FORMATION,Targeted treatment in colon carcinoma,Colon carcinoma,MDM2 in colon carcinoma,MDM2 gene amplification,MDM2,MDM2 protein expression},
  language     = {eng},
  number       = {2},
  pages        = {197--203},
  title        = {MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?},
  url          = {http://dx.doi.org/10.1007/s00428-010-1012-7},
  volume       = {458},
  year         = {2011},
}

Chicago
Hav, Monirath, Louis Libbrecht, Liesbeth Ferdinande, Piet Pattyn, Stéphanie Laurent, Marc Peeters, Marleen Praet, and Patrick Pauwels. 2011. “MDM2 Gene Amplification and Protein Expressions in Colon Carcinoma: Is Targeting MDM2 a New Therapeutic Option?” Virchows Archiv 458 (2): 197–203.
APA
Hav, M., Libbrecht, L., Ferdinande, L., Pattyn, P., Laurent, S., Peeters, M., Praet, M., et al. (2011). MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option? VIRCHOWS ARCHIV, 458(2), 197–203.
Vancouver
1.
Hav M, Libbrecht L, Ferdinande L, Pattyn P, Laurent S, Peeters M, et al. MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option? VIRCHOWS ARCHIV. 2011;458(2):197–203.
MLA
Hav, Monirath, Louis Libbrecht, Liesbeth Ferdinande, et al. “MDM2 Gene Amplification and Protein Expressions in Colon Carcinoma: Is Targeting MDM2 a New Therapeutic Option?” VIRCHOWS ARCHIV 458.2 (2011): 197–203. Print.